ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO794

Establishment of Diagnostic Criteria for Tubulointerstitial Nephritis with IgM-Positive Plasma Cells (IgMPC-TIN)

Session Information

Category: Pathology and Lab Medicine

  • 1800 Pathology and Lab Medicine


  • Takahashi, Naoki, Fukui Daigaku, Fukui, Fukui, Japan
  • Nishikawa, Yudai, Fukui Daigaku, Fukui, Fukui, Japan
  • Watanabe, Yuki, Fukui Daigaku, Fukui, Fukui, Japan
  • Nishikawa, Sho, Fukui Daigaku, Fukui, Fukui, Japan
  • Nishimori, Kazuhisa, Fukui Daigaku, Fukui, Fukui, Japan
  • Fukushima, Sachiko, Fukui Daigaku, Fukui, Fukui, Japan
  • Kobayashi, Mamiko, Fukui Daigaku, Fukui, Fukui, Japan
  • Kimura, Hideki, Fukui Daigaku, Fukui, Fukui, Japan
  • Kasuno, Kenji, Fukui Daigaku, Fukui, Fukui, Japan
  • Iwano, Masayuki, Fukui Daigaku, Fukui, Fukui, Japan

We proposed the IgMPC-TIN disease concept in 2017, and this disease concept is gradually gaining recognition in Japan. However, there are no clear diagnostic criteria for diagnosing IgMPC-TIN. We attempted to develop diagnostic criteria for IgMPC-TIN from both clinical and histological parameters or from only clinical parameters using cases collected from multiple institutions.


A total of 118 renal biopsy samples were collected from 61 patients with suspected IgMPC-TIN and 57 patients with other interstitial lesions from our hospital and national collaborating centers, and we performed double staining (IgM and CD138) using the immunoenzymatic method. Patients with M protein in their blood or urine and patients with diabetes mellitus were established as exclusion criteria. Then several nephrologists classified each case that did not meet the exclusion criteria from +3 (typical IgMPC-TIN) to −3 (not IgMPC-TIN at all). Based on 49 cases judged as +3 and 56 cases judged as −3, a decision tree-based diagnostic algorithm was created in JMP. Finally, the sensitivity and specificity of the diagnostic criteria created were calculated.


In the diagnostic criteria consisting of histological and clinical parameters, the most important requirement was a maximum IgMPC infiltration count of ≥20/high magnification field of view (7400 µm2). The next most important requirement was the presence of urinary sugar, and the next requirement was the presence of primary biliary cholangitis (PBC). For diagnostic criteria consisting only of clinical parameters, the most important requirement was a serum IgM level of 267 or higher, followed by the presence of Fanconi syndrome. Sensitivity and specificity of each diagnostic criterion were 97.9 and 100% for histological and clinical parameters and only for clinical parameters. Although we consider diagnostic criteria that include histological parameters to be the gold standard, diagnostic criteria based solely on clinical parameters are also sufficiently accurate.


We analyze the clinical characteristics of IgMPC-TIN cases and develop criteria for the diagnosis of IgMPC-TIN based on histological and clinical parameters.


  • Government Support – Non-U.S.